Corbus Pharmaceuticals Advances Key Trials as Leadership Team Expands — Corbus Pharmaceuticals Holdings, Inc.

Event summary

FDA cleared Corbus to begin TEMPO-1 Phase 3 trial for CRB-701 in oropharyngeal cancer, with enrollment starting September 2026.
CANYON-1 Phase 1b study of CRB-913 in obesity completed, topline data expected September 2026.
Corbus appointed new Chief Medical Officer, Chief Business Officer, and Board Member to strengthen leadership for registrational studies and commercialization.
Q2 2026 net loss widened to $35.0 million from $17.7 million in Q2 2025 due to increased clinical development expenses.

The big picture

Corbus Pharmaceuticals is positioning itself for critical milestones in both oncology and obesity with the advancement of its key trials. The strategic hiring of experienced leaders suggests a focus on navigating regulatory pathways and preparing for commercialization, which is crucial as the company competes in highly competitive therapeutic areas. The financial losses highlight the significant investment required to bring these therapies to market.

What we're watching

Regulatory Momentum: The pace at which CRB-701 advances through the TEMPO-1 trial will determine its potential for accelerated approval in oropharyngeal cancer.
Commercialization Readiness: Whether Corbus's new leadership team can effectively guide the company through registrational studies and prepare for market entry.
Financial Sustainability: How long Corbus’s current cash reserves will last, given the increased operating expenses and the timeline to potential revenue from CRB-701 and CRB-913.